Home | Welcome to Contract Pharma   
Last Updated Wednesday, March 4 2015


Topics - Drug Discovery

Refine by Date:
From: To:
Published February 27, 2015
Goal is to identify best-in-class RORγ inhibitors to treat autoimmune disease Read More »
Published February 25, 2015
Opens newly expanded office Read More »
Published February 20, 2015
To use TBK1 to study ALS disease mechanisms and screen for drug candidates Read More »
Published February 18, 2015
Calias responsible for ERT programs and driving scientific and strategic direction Read More »
Published February 17, 2015
Will house commercial, corporate analytics, and business development staff Read More »
Published February 13, 2015
Expands translational oncology drug discovery services Read More »
Published February 12, 2015
Jayaraman and Kemmerling take on Discovery and Preclinical roles Read More »
Published February 6, 2015
To generate bispecific molecules against multiple targets Read More »
Published February 3, 2015
Foehr brings more than 20 years of pharma experience Read More »
Published February 2, 2015
Advances MS Research Read More »
By Adele Graham-King, Contributing Editor
Published January 29, 2015
To use or not to use unlicensed drugs? That is the question. Read More »
Published January 22, 2015
Will research and develop approaches to CAR T cell therapy in cancer Read More »
Published January 20, 2015
Aims to improve asset development and delivery timelines Read More »
Published January 19, 2015
To apply discovery and technology platforms to develop inhibitors for addictive disorders Read More »
Published January 14, 2015
Gains exclusive rights to oncology target Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On